MyoPAXon Platform
Limb Girdle Muscular Dystrophy
Key Facts
About Myogenica
Myogenica is a private, preclinical-stage biotech developing MyoPAXon, a universal iPSC-derived muscle stem cell therapy for muscular dystrophies. Founded by leading academic researchers and an experienced entrepreneur, the company leverages over a decade and $10M in grant-funded research from the University of Minnesota. With a Phase I trial in Duchenne muscular dystrophy slated for 2025, Myogenica aims to address a significant unmet need with a potentially durable, one-time treatment that regenerates functional muscle.
View full company profileAbout Myogenica
Myogenica is a private, preclinical-stage biotech developing MyoPAXon, a universal iPSC-derived muscle stem cell therapy for muscular dystrophies. Founded by leading academic researchers and an experienced entrepreneur, the company leverages over a decade and $10M in grant-funded research from the University of Minnesota. With a Phase I trial in Duchenne muscular dystrophy slated for 2025, Myogenica aims to address a significant unmet need with a potentially durable, one-time treatment that regenerates functional muscle.
View full company profile